聴覚障害(Hearing Disorders):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Hearing Disorders - Pipeline Review, H2 2014
◆商品コード:GMDHC5811IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月30日
◆ページ数:94
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における聴覚障害(Hearing Disorders)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・聴覚障害(Hearing Disorders)の概要
・聴覚障害(Hearing Disorders)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・聴覚障害(Hearing Disorders)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・聴覚障害(Hearing Disorders)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・聴覚障害(Hearing Disorders)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Hearing Disorders – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Hearing Disorders – Pipeline Review, H2 2014’, provides an overview of the Hearing Disorders’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hearing Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hearing Disorders and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hearing Disorders
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hearing Disorders and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hearing Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hearing Disorders pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hearing Disorders
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hearing Disorders pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Hearing Disorders Overview 9
Therapeutics Development 10
Pipeline Products for Hearing Disorders – Overview 10
Pipeline Products for Hearing Disorders – Comparative Analysis 11
Hearing Disorders – Therapeutics under Development by Companies 12
Hearing Disorders – Therapeutics under Investigation by Universities/Institutes 14
Hearing Disorders – Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Hearing Disorders – Products under Development by Companies 18
Hearing Disorders – Products under Investigation by Universities/Institutes 19
Hearing Disorders – Companies Involved in Therapeutics Development 20
Affichem 20
AudioCure Pharma GmbH 21
Edison Pharmaceuticals, Inc. 22
Fate Therapeutics, Inc. 23
Living Cell Technologies Limited 24
Novartis AG 25
Otologic Pharmaceutics, Inc. 26
Pharmicell Co., Ltd. 27
Quark Pharmaceuticals, Inc. 28
Sound Pharmaceuticals, Inc. 29
uniQure NV 30
Hearing Disorders – Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Combination Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
(acetylcysteine + disufenton sodium) – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
AC-002 – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
AC-102 – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
AC-103 – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
AC-104 – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
AF-243 – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
AMT-090 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
AUT-00063 – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Cellgram for Severe Hard of Hearing – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
CGF-166 – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Drugs to Inhibit Rho Kinase for Hearing Loss – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Neuroprotectin D1 – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
NTCELL – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
OT-0001 Analogs – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
P-13 – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
siRNA for CNS Disorders – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Small Molecules to Inhibit Gamma Secretase for Hearing Loss – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
sodium thiosulfate – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
SPI-1005 – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
SPI-3005 – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
SPI-5557 – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Stem Cell Therapy for Hearing Disorders – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
transplatin – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
vatiquinone – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Hearing Disorders – Recent Pipeline Updates 72
Hearing Disorders – Dormant Projects 81
Hearing Disorders – Discontinued Products 82
Hearing Disorders – Product Development Milestones 83
Featured News & Press Releases 83
Jun 02, 2014: Adherex Announces Results From Two Sodium Thiosulfate Phase 3 Studies Presented at the 50th American Society of Clinical Oncology Meeting 83
Apr 22, 2014: Adherex Announces Two Sodium Thiosulfate Presentations for Prevention of Ototoxicity in Children at ASCO Meeting 85
Nov 05, 2013: Sound Pharmaceuticals successfully completes its first Phase 2 clinical trial with SPI-1005 involving iPod or noise induced hearing loss 86
Oct 07, 2011: Adherex Reports Meeting With FDA’S Pediatric Subcommittee Of Oncologic Drugs Advisory Committee On Development Of Sodium Thiosulfate Injection 87
Jun 28, 2010: Fate Therapeutics Receives Red Herring’s North America 100 Award For Advancing Stem Cell Technology And New Medicines 87
Feb 04, 2010: Fate Therapeutics Receives Allowance Of First U.S. Patent For Induced Pluripotent Stem Cell Technology 88
Dec 01, 2009: Fate Therapeutics’ IPSC Technology Awarded Top Industry Honors For Small Molecule And Protein Reprogramming Breakthroughs 89
Nov 16, 2009: Fate Therapeutics Closes $30 Million Series B Financing 90
Aug 19, 2009: Sound Pharmaceuticals Receives An Office of Naval Research Award for Its Hearing Loss Research and Development 91
Jul 23, 2008: Sound Pharmaceuticals Files Second IND with the FDA For The Prevention Of Chemotherapy Induced Hearing Loss In Advanced Stage Cancer 91
Appendix 93
Methodology 93
Coverage 93
Secondary Research 93
Primary Research 93
Expert Panel Validation 93
Contact Us 94
Disclaimer 94

[List of Tables]
Number of Products under Development for Hearing Disorders, H2 2014 10
Number of Products under Development for Hearing Disorders - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
Hearing Disorders - Pipeline by Affichem, H2 2014 20
Hearing Disorders - Pipeline by AudioCure Pharma GmbH, H2 2014 21
Hearing Disorders - Pipeline by Edison Pharmaceuticals, Inc., H2 2014 22
Hearing Disorders - Pipeline by Fate Therapeutics, Inc., H2 2014 23
Hearing Disorders - Pipeline by Living Cell Technologies Limited, H2 2014 24
Hearing Disorders - Pipeline by Novartis AG, H2 2014 25
Hearing Disorders - Pipeline by Otologic Pharmaceutics, Inc., H2 2014 26
Hearing Disorders - Pipeline by Pharmicell Co., Ltd., H2 2014 27
Hearing Disorders - Pipeline by Quark Pharmaceuticals, Inc., H2 2014 28
Hearing Disorders - Pipeline by Sound Pharmaceuticals, Inc., H2 2014 29
Hearing Disorders - Pipeline by uniQure NV, H2 2014 30
Assessment by Monotherapy Products, H2 2014 31
Assessment by Combination Products, H2 2014 32
Number of Products by Stage and Target, H2 2014 34
Number of Products by Stage and Mechanism of Action, H2 2014 36
Number of Products by Stage and Route of Administration, H2 2014 38
Number of Products by Stage and Molecule Type, H2 2014 40
Hearing Disorders Therapeutics - Recent Pipeline Updates, H2 2014 72
Hearing Disorders - Dormant Projects, H2 2014 81
Hearing Disorders - Discontinued Products, H2 2014 82

[List of Figures]
Number of Products under Development for Hearing Disorders, H2 2014 10
Number of Products under Development for Hearing Disorders - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Products, H2 2014 17
Assessment by Monotherapy Products, H2 2014 31
Number of Products by Top 10 Targets, H2 2014 33
Number of Products by Stage and Top 10 Targets, H2 2014 34
Number of Products by Top 10 Mechanism of Actions, H2 2014 35
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 36
Number of Products by Top 10 Routes of Administration, H2 2014 37
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 38
Number of Products by Top 10 Molecule Types, H2 2014 39
Number of Products by Stage and Top 10 Molecule Types, H2 2014 40

【掲載企業】

Affichem
AudioCure Pharma GmbH
Edison Pharmaceuticals, Inc.
Fate Therapeutics, Inc.
Living Cell Technologies Limited
Novartis AG
Otologic Pharmaceutics, Inc.
Pharmicell Co., Ltd.
Quark Pharmaceuticals, Inc.
Sound Pharmaceuticals, Inc.
uniQure NV

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[聴覚障害(Hearing Disorders):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆